Navigation Links
MEDRAD Molecular Imaging Earns Top Rank in Innovation
Date:2/13/2009

New technology reduces radiation exposure, eliminates workflow complexity, and enables patient-scheduling flexibility

WARRENDALE, Pa., Feb. 13 /PRNewswire/ -- MEDRAD's Intego(TM) PET Infusion System has been named one of Medical Imaging Magazine's top eight most innovative products of the year. The magazine designated its top eight based on what its readership considers to be the most far-reaching, game changing or otherwise groundbreaking medical devices on the market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO )

MEDRAD's Intego PET Infusion System automatically measures and delivers patient-specific Fluorodeoxyglucose (FDG) doses on demand. With on-board dosimetry, the system can deliver precise, repeatable FDG doses within +/- 2% of the measured dose. The Intego also minimizes FDG handling and is fully shielded, reducing radiation exposure by more than 20% compared to conventional (syringe-based) FDG delivery methods.

"Intego technology is raising the standard of care in FDG delivery," says Doug Descalzi, Executive Director of MEDRAD's Molecular Imaging business. "Healthcare professionals gain precision, flexibility and control over workflow, which can help any PET practice grow clinically and safely."

More detailed information on MEDRAD's Intego PET Infusion System is available at www.medrad.com/FDGdelivery

About MEDRAD

MEDRAD, Inc., is a worldwide leading provider of medical devices and services that enable and enhance imaging and therapeutic procedures of the human body. For diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. The company also offers products used in vascular intervention. MEDRAD's total 2007 revenues were $525 million. In 2003, MEDRAD received the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. More company information is available at www.medrad.com.

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.

Cautionary statement regarding forward-looking statements.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC. undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.


'/>"/>
SOURCE MEDRAD, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
2. MEDRAD Plant Named IndustryWeek Magazine Award Finalist
3. MEDRAD Mobile MR Injector Meets Challenges of MR Trailers
4. MEDRAD(R) Revenues Grow 10 Percent in 2007
5. MEDRAD and PETNET Solutions Partner for Innovative FDG Delivery
6. MEDRAD Receives FDA 510(k) Clearance for Wireless MR Infusion System
7. MEDRAD Multi Vendor Service Forms Alliance with Wetsco
8. MEDRAD Builds on Success of P3T Cardiac CT Injection Software
9. MEDRAD Sponsors PET Research with University of Zurich
10. A new molecular zip code, and a new drug target for Huntingtons disease
11. New knock-out gene model provides molecular clues to breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... Washington, DC (PRWEB) , ... July 26, 2017 ... ... Arise Infusion is pleased to now offer a major advancement in drug therapy ... their lives. Ocrevus (pronounced Ah-creh-vus) is a novel B cell targeted therapy ...
(Date:7/26/2017)... Yorba Linda, Ca (PRWEB) , ... July 26, 2017 , ... ... of optimize lyophilization processes. Inconsistent results freeze drying samples and a lengthy freeze dry ... , This webinar will discuss freeze drying techniques, as well as new accessories and ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... host its 2017 Process Validation and Process Validation Statistics Conferences in Bethesda, ... process validation lifecycle challenges faced by process validation professionals and statisticians today. ...
(Date:7/26/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of education, ... announce the 106 college athletes with type 1 diabetes who will receive scholarships as ... 1 Foundation has bestowed a total of 271 college scholarships to athletes with type ...
(Date:7/26/2017)... ... July 26, 2017 , ... IDC-Eating Disorder Care ... the treatment program located in Royal Oak, Michigan. IDC, formerly known as ... focused on providing the highest standards in the field of eating disorder treatment in ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... , July 13, 2017 It should come ... States is in the midst of a crippling ... , since 1999, the number of overdose deaths from opiate-based ... in over half a million dead from 2001 to 2015". ... oxycodone, and hydrocodone has similarly quadrupled, drawing a compelling link ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
(Date:7/11/2017)... SARASOTA, Fla. , July 11, 2017  Dr. Echenberg, founder of ... Dilator therapy program to patients who suffer from painful intercourse and other ... vaginismus and vaginal atrophy due to menopause. ... VuVatech LLC ... Dilators , created by Sarasota, Florida -based start-up company, ...
Breaking Medicine Technology: